These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1372625)

  • 1. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction.
    Tanswell P; Tebbe U; Neuhaus KL; Gläsle-Schwarz L; Wojcik J; Seifried E
    J Am Coll Cardiol; 1992 Apr; 19(5):1071-5. PubMed ID: 1372625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
    Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
    Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.
    Hoffmeister HM; Kastner C; Szabo S; Beyer ME; Helber U; Kazmaier S; Baumbach A; Wendel HP; Heller W
    Am J Cardiol; 2000 Aug; 86(3):263-8. PubMed ID: 10922430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction.
    Seifried E; Tanswell P; Ellbrück D; Haerer W; Schmidt A
    Thromb Haemost; 1989 Jun; 61(3):497-501. PubMed ID: 2508258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
    Tanswell P; Modi N; Combs D; Danays T
    Clin Pharmacokinet; 2002; 41(15):1229-45. PubMed ID: 12452736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency.
    Meierhenrich R; Carlsson J; Seifried E; Pfarr E; Smolarz A; Neuhaus KL; Tebbe U
    Int J Cardiol; 1998 Jun; 65(1):57-63. PubMed ID: 9699932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. DouBLE Study Investigators. Double Bolus Lysis Efficacy.
    Bleich SD; Adgey AA; McMechan SR; Love TW
    Am Heart J; 1998 Oct; 136(4 Pt 1):741-8. PubMed ID: 9778080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
    Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.
    Kostis JB; Dockens RC; Thadani U; Bethala V; Pepine C; Leimbach W; Vachharajani N; Raymond RH; Stouffer BC; Tay LK; Shyu WC; Liao WC
    Clin Pharmacokinet; 2002; 41(6):445-52. PubMed ID: 12074692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
    Diefenbach C; Erbel R; Pop T; Mathey D; Schofer J; Hamm C; Ostermann H; Schmitz-Hübner U; Bleifeld W; Meyer J
    Am J Cardiol; 1988 May; 61(13):966-70. PubMed ID: 2452563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction.
    Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators
    N Engl J Med; 1997 Oct; 337(16):1124-30. PubMed ID: 9340504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.
    Koster RW; Cohen AF; Hopkins GR; Beier H; Günzler WA; van der Wouw PA
    Thromb Haemost; 1994 Nov; 72(5):740-4. PubMed ID: 7534946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
    Van de Werf F; Vanhaecke J; de Geest H; Verstraete M; Collen D
    Circulation; 1986 Nov; 74(5):1066-70. PubMed ID: 2429783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
    Wall TC; Califf RM; George BS; Ellis SG; Samaha JK; Kereiakes DJ; Worley SJ; Sigmon K; Topol EJ
    J Am Coll Cardiol; 1992 Mar; 19(3):482-9. PubMed ID: 1537998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
    Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH
    Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.
    Vanderschueren S; Barrios L; Kerdsinchai P; Van den Heuvel P; Hermans L; Vrolix M; De Man F; Benit E; Muyldermans L; Collen D
    Circulation; 1995 Oct; 92(8):2044-9. PubMed ID: 7554180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
    Neuhaus KL; von Essen R; Tebbe U; Vogt A; Roth M; Riess M; Niederer W; Forycki F; Wirtzfeld A; Maeurer W
    J Am Coll Cardiol; 1992 Apr; 19(5):885-91. PubMed ID: 1552106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
    Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
    Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.